Regeneron Pharmaceuticals Inc. buy Argus
Summary
This prediction is currently active. With a performance of 39.68% the BUY prediction by Argus is a big success. This prediction currently runs until 15.09.24. The prediction end date can be changed by Argus at any time. Argus has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 0.280% | 0.280% |
iShares Core DAX® | 1.937% | 1.473% |
iShares Nasdaq 100 | -1.186% | -0.040% |
iShares Nikkei 225® | 1.938% | 4.205% |
iShares S&P 500 | -0.023% | 0.109% |
Comments by Argus for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Argus for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
25.06.24
25.06.25
22:26